Hepatitis News : Abbott Announces Phase III Trials of Its Potent Hep C Direct Acting Agents

A Smart + Strong Site
Subscribe to:
Hepatitis E-newsletter
Join Us:

Back to home » Hepatitis News » December 2012


emailprint

December 4, 2012

Abbott Announces Phase III Trials of Its Potent Hep C Direct Acting Agents

Following on the heels of game-changing data showing its investigatory hepatitis C cocktail produced cures in over 93 percent of  study participants, Abbott has announced Phase III clinical trials of three direct acting agents. Known as Aviator, the Phase IIb results were presented at the annual meeting of the American Association for the Study of Liver Disease (AASLD) in Boston.

These further clinical trial sites will spread across 29 countries and include more than 2,000 patients with hep C genotype 1—the most common in the United States and the most difficult to treat with today's interferon-based therapies. The direct acting agents under study include ABT-450/r, which is a protease inhibitor that's taken with ritonavir; the NS5A inhibitor ABT-267; and a non-nucleoside polymerase inhibitor called ABT-333. Non-cirrhotic patients will undergo 12 weeks of therapy, while cirrhotic patients will take the cocktail for 12 or 24 weeks. At the completion of treatment, all patients will be followed for 48 weeks. Abbott will use a co-formulated tablet of ABT-450/4 and ABT-267 in the trial.

To read the Abbott statement, click here.

Search: Hepatitis C, HCV, hep C, Abbott, Phase III trials, DAA, direct acting agent, cure, ABT-450/r, protease inhibitor, ritonavir, NS5A inhibitor, ABT-267, non-nucleoside, polymerase inhibitor, ABT-333, cirrhotic, genotype 1, American Association for the Study of Liver Disease, AASLD.


Scroll down to comment on this story. Click here to visit the Hep Forums and ask questions about this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The Hep team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)


[Go to top]

Quick Links
Current Issue
Forums
Poll
Blogs
Hep TV
Calendar
Services Directory
Conference News
Top Stories
Treatment News
Hep Exclusives
All About Hepatitis
• Hepatitis A
Transmission
Prevention
Treatment
• Hepatitis B
Transmission
Prevention
Treatment
• Hepatitis C
Transmission
Prevention
Treatment
HCV/HIV Coinfection
Help Paying For Meds
Clinical Trials
TALK TO US
Tell us what you think
Poll
Would you consider using medical marijuana to help ease side-effects of hepatitis C treatment?
Yes
No
Not sure


Survey
USA Today/Hepatitis C Awareness Survey

Hepatitis C Reader Survey
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.